Martin Koenig

Title: Martin Koenig: Innovator in Immunoconjugate Therapy

Introduction

Martin Koenig is a notable inventor based in Wiesbaden, Germany. He has made significant contributions to the field of immunotherapy, particularly through his innovative work on immunoconjugates targeting CD138. His research has the potential to impact the treatment of diseases associated with target cells expressing CD138.

Latest Patents

Martin Koenig holds a patent for the "Uses of immunoconjugates targeting CD138." This patent discloses a method and composition for treating diseases associated with target cells expressing CD138 in a multiple dose regimen. The immunoconjugate comprises an engineered targeting antibody that targets CD138 expressing cells and an effector molecule. The method involves administering the immunoconjugate in a multiple dose regimen, which includes at least two doses. The aggregate dose administered within an active treatment cycle is either an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. This innovative approach aims to exceed the dose that results in dose limiting toxicity (DLT) when administered as a single dose.

Career Highlights

Throughout his career, Martin Koenig has worked with prominent companies in the biotechnology sector. He has been associated with Biotest AG and Immunogen, Inc., where he has contributed to advancements in immunotherapy and drug development.

Collaborations

Martin has collaborated with notable professionals in his field, including Gregor Schulz and Frank Osterroth. These collaborations have further enriched his research and development efforts.

Conclusion

Martin Koenig's work in immunoconjugate therapy represents a significant advancement in the treatment of diseases associated with CD138. His innovative patent and collaborations highlight his commitment to improving therapeutic options in the field of immunotherapy.